Please login to the form below

Not currently logged in
Email:
Password:

Evan Lippman joins Aileron Therapeutics

He has experience at EMD Serono, Pfizer and AstraZeneca
Evan Lippman joins Aileron Therapeutics

Aileron Therapeutics has added to its senior team with the appointment of Evan Lippman as its first chief financial and business officer.

The addition comes as the US biopharma prepares to advance its lead oncology candidate ALRN-6924 into clinical trials.

In Lippman Aileron gains the expertise of a man with great experience in life sciences. Most recently Lippman help a senior VP role at EMD Serono heading the strategy for its US neurology franchise.

Highlights of his career include a spell as executive director at AstraZeneca where he led on huge brands such as Crestor (rosuvastatin calcium) and Nexium (esomeprazole) and heading US business development at the same company.

Lippman's other big pahrma experience includes a period at Pfizer as executive director, worldwide business development and strategic planning.

12th January 2015

From: Research, Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...
Medopad: the up and coming unicorn transforming remote patient monitoring
Blue Latitude Health speaks to Medopad’s Martha Carruthers to learn how the start-up’s modular apps are helping patients with complex diseases....

Infographics